Table 3. 28-Day Risk Differences and Risk Ratios of Hospitalization or Death by Route of Monoclonal Antibody Administrationa.
| Outcome | No. (%) of patients | Absolute risk difference, % | Adjusted risk ratioa | ||||
|---|---|---|---|---|---|---|---|
| Subcutaneous (969 total patients and 721 infused at same site) | Intravenous (1216 total patients and 441 infused at same site) | Unadjusted | Adjustedb | 95% CI | Adjusted (95% CI) | P value | |
| All patients receiving infusions | |||||||
| Hospitalization or death | 27 (2.8) | 21 (1.7) | 1.1 | 1.5 | −0.6 to 3.5 | 1.7 (1.0 to 3.0) | .06 |
| Hospitalization | 27 (2.8) | 20 (1.6) | 1.1 | 1.5 | −0.4 to 3.4 | 1.8 (1.0 to 3.2) | .05 |
| Death | 1 (0.1) | 3 (0.2) | −0.1 | 0.3 | −6.1 to 5.4 | 0.5 (0.1 to 4.5) | .51 |
| ED or hospitalization | 47 (4.8) | 71 (5.8) | −1.0 | −0.9 | −2.8 to 0.9 | 0.9 (0.6 to 1.2) | .38 |
| Patients receiving infusion at the same site | |||||||
| Hospitalization or death | 17 (2.4) | 4 (0.9) | 1.5 | 1.3 | −2.6 to 5.2 | 2.7 (0.9 to 7.7) | .08 |
| Hospitalization | 17 (2.4) | 4 (0.9) | 1.5 | 1.3 | −2.6 to 5.2 | 2.7 (0.9 to 7.7) | .08 |
| Death | 1 (0.1) | 1 (0.2) | −0.1 | −0.2 | −9.0 to 8.5 | 0.8 (0.0 to 12.9) | .85 |
| ED or hospitalization | 38 (5.3) | 26 (5.9) | −0.6 | −1.2 | −3.8 to 1.4 | 0.9 (0.6 to 1.5) | .66 |
Abbreviation: ED, emergency department.
a
For patients treated at all health system facilities, patients were treated subcutaneously from July 20 to September 20, 2021, and patients were treated intravenously from July 15 to September 29, 2021. For patients treated at the same health system facilities, patients were treated subcutaneously from September 9 to 29, 2021, and patients were treated intravenously from July 15 to September 29, 2021.
b
Model adjusted for age, sex, Black race, and vaccination status.